Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
NCT04346615 · Pfizer · PHASE2/PHASE3 · terminated · last registry update 2024-05-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of enrollment due to evolution of COVID-19 pandemic with reduction in patients at risk for severe disease and growing number of effective alternative therapies” | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RAMP1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-27Results posted on the registry: Pfizer, BHV-3500 (zavegepant) + Placebo (NCT04804033)
- 2025-03-27Also stopped (terminated): Pfizer, BHV-3500 (zavegepant) + Placebo (NCT04804033)
- 2025-01-06Results posted on the registry: Pfizer, Zavegepant (NCT05960032)
- 2024-10-01Phase 3 first posted: Esbjerg Hospital - University Hospital of Southern Denmark, Pramlintide Acetate 1 MG/ML + Semaglutide Pen Injector (NCT06619015)
- 2024-10-01Results posted on the registry: Pfizer, Zavegepant 100mg non-enteric coated soft gel capsule + Zavegepant 100mg immediate release tablet (NCT06137703)
- 2024-07-19Results posted on the registry: Pfizer, Zavegepant + Placebo (NCT04987944)
- 2024-07-19Also stopped (terminated): Pfizer, Zavegepant + Placebo (NCT04987944)
- 2024-03-27Results posted on the registry: Xeris Pharmaceuticals, PRAM9 + Regular Insulin + Pramlintide (NCT04074317)
- 2023-10-27Phase 3 first posted: Pfizer, Zavegepant 10 mg + Placebo - Control 1 (NCT06103734)
- 2023-09-21Phase 3 first posted: McGill University Health Centre/Research Institute of the McGill University Health Centre, Pramlintide + Lyumjev (NCT06046417)
- 2023-08-14Phase 3 first posted: Pfizer, Zavegepant + Placebo (NCT05989048)
- 2023-06-28Also stopped (withdrawn): H. Lee Moffitt Cancer Center and Research Institute, Pramlintide (NCT04252612)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision